Streetbeat News

SKYE

Skye Bioscience Inc

https://www.emeraldbio.life/

CEO

Brian Murphy

Employees

11

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.

Open

3.19

Mkt cap

90M

Volume

124K

High

3.27

P/E Ratio

5.62

52-wk high

19.41

Low

2.93

Div yield

N/A

52-wk low

2.31

Skye Bioscience's Nimacimab shows promising Phase 1 safety data and is in Phase 2 trials, potentially revolutionizing obesity treatment with minimal neuropsychiatric side effects. The drug's design avoids issues seen in earlier CB1 inhibitors and suggests fat-specific weight loss, lean muscle preservation, and appetite regulation.

Portfolio Pulse from

December 10, 2024 | 1:45 pm

Skye Bioscience, Inc. (NASDAQ:SKYE) held its Q3 2024 earnings conference call on November 7, 2024. Key company participants included Bernie Hertel, Punit Dhillon, Kaitlyn Arsenault, Chris Twitty, and Dr. Puneet Arora. Analysts from Piper Sandler, Oppenheimer, ScotiaBank, Craig-Hallum, and Cantor Fitzgerald participated in the call.

Portfolio Pulse from

November 08, 2024 | 4:00 am

Skye Bioscience, a clinical-stage biopharmaceutical company, reported its financial results for Q3 2024 and highlighted recent corporate achievements.

Portfolio Pulse from

November 07, 2024 | 9:15 pm

Scotiabank has initiated coverage on Skye Bioscience with a Sector Outperform rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:51 pm

Skye Bioscience shares are trading higher, potentially in sympathy with Novo Nordisk's positive Phase 2a data announcement for Monlunabant and confidence in its Nimacimab development plan.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 2:29 pm

Skye Bioscience has commented on Novo Nordisk's recent announcement of Phase 2a topline data with Monlunabant, expressing confidence in its own Nimacimab clinical development plan. Skye believes the 16-week weight loss data supports the mechanism of action targeting peripheral CB1 receptors.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:05 am

Novo Nordisk's phase 2a trial results for monlunabant, a CB1 inverse agonist, showed limited additional weight loss at higher doses, impacting stocks of Corbus Pharmaceuticals and Skye Bioscience. Both companies are developing similar weight loss drugs. Analysts have adjusted price targets for Corbus, and Skye's stock dropped significantly.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 7:18 pm

Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 5:57 pm

Skye Bioscience shares are trading lower in sympathy with Novo Nordisk after Novo Nordisk reported results from its Phase 2a trial of Monlunabant in obesity.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:43 pm

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.